TY - JOUR
T1 - Psychological co-morbidities in COPD
T2 - Targeting systemic inflammation, a benefit for both?
AU - Pelgrim, Charlotte E.
AU - Peterson, Julia D.
AU - Gosker, Harry R.
AU - Schols, Annemie M. W. J.
AU - van Helvoort, Ardy
AU - Garssen, Johan
AU - Folkerts, Gert
AU - Kraneveld, Aletta D.
N1 - Funding Information:
This work was supported by an LSH-TKI Lung Foundation grant 10.2.16.119 , 2017 ‘Food for thought and active lifestyle in COPD’.
Publisher Copyright:
© 2018 The Authors
PY - 2019/1/5
Y1 - 2019/1/5
N2 - COPD is a chronic lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. Furthermore, COPD is often characterized by extrapulmonary manifestations and comorbidities worsening COPD progression and quality of life. A neglected comorbidity in COPD management is mental health impairment defined by anxiety, depression and cognitive problems. This paper summarizes the evidence for impaired mental health in COPD and focuses on current pharmacological intervention strategies. In addition, possible mechanisms in impaired mental health in COPD are discussed with a central role for inflammation.Many comorbidities are associated with multi-organ-associated systemic inflammation in COPD. Considering the accumulative evidence for a major role of systemic inflammation in the development of neurological disorders, it can be hypothesized that COPD-associated systemic inflammation also affects the function of the brain and is an interesting therapeutic target for nutra- and pharmaceuticals.
AB - COPD is a chronic lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. Furthermore, COPD is often characterized by extrapulmonary manifestations and comorbidities worsening COPD progression and quality of life. A neglected comorbidity in COPD management is mental health impairment defined by anxiety, depression and cognitive problems. This paper summarizes the evidence for impaired mental health in COPD and focuses on current pharmacological intervention strategies. In addition, possible mechanisms in impaired mental health in COPD are discussed with a central role for inflammation.Many comorbidities are associated with multi-organ-associated systemic inflammation in COPD. Considering the accumulative evidence for a major role of systemic inflammation in the development of neurological disorders, it can be hypothesized that COPD-associated systemic inflammation also affects the function of the brain and is an interesting therapeutic target for nutra- and pharmaceuticals.
KW - COPD
KW - Anxiety
KW - Depression
KW - Cognitive impairment
KW - Systemic inflammation
KW - Pharmaceutical and nutritional interventions
KW - OBSTRUCTIVE PULMONARY-DISEASE
KW - NICOTINIC ACETYLCHOLINE-RECEPTOR
KW - MILD COGNITIVE IMPAIRMENT
KW - WHITE-MATTER LESIONS
KW - VITAMIN-D DEFICIENCY
KW - MULTI-NUTRIENT DIET
KW - QUALITY-OF-LIFE
KW - ALZHEIMERS-DISEASE
KW - OXIDATIVE STRESS
KW - MOUSE MODEL
U2 - 10.1016/j.ejphar.2018.10.001
DO - 10.1016/j.ejphar.2018.10.001
M3 - (Systematic) Review article
C2 - 30336140
SN - 0014-2999
VL - 842
SP - 99
EP - 110
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -